comparemela.com
Home
Live Updates
Data Demonstrating Long-Term Improvement in Depression in Ca
Data Demonstrating Long-Term Improvement in Depression in Ca
Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023
More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological supportOpen label phase 2 study,... | May 26, 2023
Related Keywords
United States ,
United Kingdom ,
London ,
City Of ,
American ,
Guy Goodwin ,
Manish Agrawal ,
Exchange Commission ,
Nasdaq ,
Linkedin ,
Drug Administration ,
Sunstone Therapies ,
Annual Meeting ,
American Society ,
Clinical Oncology ,
Chief Medical Officer ,
Chief Executive Officer ,
Principal Investigator ,
New England Journal ,
Breakthrough Therapy ,
Innovative Licensing ,
Access Pathway ,
Securities Act ,
Private Securities Litigation Reform Act ,
Compass Pathways Plc Stock Exchange ,
News ,
Information ,
Press Release ,
More ,
Han ,
Calf ,
F ,
The ,
Patients ,
Remonstrated ,
Remission ,
Depression ,
It ,
8 ,
After ,
Single ,
Nose ,
35mg ,
Investigational ,
Omp360 ,
Silocybin ,
Ith ,
Psychological ,
Upportopen ,
Label ,
Hase ,
Cmps Us20451w1018 ,